From: Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
| Case | Age/Sex | Pre-existing malignancy | ICI | Duration from ICI initiation to chondritis onset | Chondritis involvement | Therapies for chondritis | ICI cessation | Outcome of chondritis | Country, (ref) |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Auricle | Nose | Airway | |||||||||
| 1 | 72/M | Hypopharyngeal carcinoma | Nivolumab | 4 months | − | − | + | PSL (0.5 mg/kg/day) after HC (300 mg) | + | Improvement after relapse | Japan, (3) |
| 2 | 68/M | Esophageal carcinoma | Nivolumab | 5 months | − | − | + | PSL (50 mg/day) | NA | Improvement | Japan, (4) |
| 3 | 72/M | Mandibular cancer | Nivolumab | 3 months | − | + | + | Inhaled GC | + | Improvement | Japan, (5) |
| 4 | 71/M | Hypopharyngeal carcinoma | Nivolumab | 10th course of ICI | − | − | + | PSL (60 mg/day) | + | Improvement | Japan, (6) |
| 5 | 66/M | Hypopharyngeal cancer | Nivolumab | 24th course of ICI | − | − | + | High-dose GC, MTX, TCZ | NA | Improvement | Japan, (7) |
| 6 | 49/M | Lower lip cancer | Pembrolizumab | 4 months | + | − | − | None | + | Improvement after relapse | Japan, Our case |
